Harvard Bioscience (HBIO) Expected to Announce Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is projected to release its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Harvard Bioscience to announce earnings of ($0.17) per share and revenue of $21.80 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. The business had revenue of $22.73 million for the quarter, compared to analyst estimates of $21.45 million.

Harvard Bioscience Trading Up 2.0%

Harvard Bioscience stock traded up $0.17 during trading hours on Tuesday, reaching $8.78. 1,408 shares of the company’s stock were exchanged, compared to its average volume of 33,062. The company has a quick ratio of 0.98, a current ratio of 1.87 and a debt-to-equity ratio of 4.94. The firm’s 50 day simple moving average is $8.14 and its 200 day simple moving average is $6.45. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $9.10. The firm has a market capitalization of $39.93 million, a PE ratio of -3.80 and a beta of 1.50.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Benchmark upped their target price on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research report on Wednesday, August 12th. Weiss Ratings cut Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.75.

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.